Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Delivery Systems: later-stage trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Delivery Systems: 4 US clinical trials tracked, none currently recruiting.
Delivery Systems is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 4 of these trials.
Enrollment posture brief
Registry condition delivery-systems
OPEN 0 | RECR 0% | LATE 3 | EARLY 1 | RANK #4115 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Delivery Systems has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Delivery Systems on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Delivery Systems is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S
NCT00773279
Novofine Autocover Safety Needle Versus BD Safety Glide
Novo Nordisk A/S
NCT00121355
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
Novo Nordisk A/S
NCT00115973
Comparison of Glycemic Control Achieved With 2 Different Needles
Novo Nordisk A/S
NCT00572052
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Delivery Systems records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Delivery Systems trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Delivery Systems page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Delivery Systems trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Novo Nordisk A/S sponsors the most Delivery Systems trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Delivery Systems condition card totals 4 registered trials; most-linked intervention Ultra-Fine needle 12.7 mm; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.